Severity: Warning
Message: fopen(/var/cpanel/php/sessions/ea-php56/ci_sessionef018a09d78aac86faec626d87aecf4dd7ea6132): failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 156
Backtrace:
File: /home/druginte/public_html/drug-new/application/controllers/Web.php
Line: 9
Function: __construct
File: /home/druginte/public_html/drug-new/index.php
Line: 292
Function: require_once
Severity: Warning
Message: session_start(): Cannot send session cookie - headers already sent by (output started at /home/druginte/public_html/drug-new/system/core/Exceptions.php:272)
Filename: Session/Session.php
Line Number: 140
Backtrace:
File: /home/druginte/public_html/drug-new/application/controllers/Web.php
Line: 9
Function: __construct
File: /home/druginte/public_html/drug-new/index.php
Line: 292
Function: require_once
Severity: Warning
Message: session_start(): Cannot send session cache limiter - headers already sent (output started at /home/druginte/public_html/drug-new/system/core/Exceptions.php:272)
Filename: Session/Session.php
Line Number: 140
Backtrace:
File: /home/druginte/public_html/drug-new/application/controllers/Web.php
Line: 9
Function: __construct
File: /home/druginte/public_html/drug-new/index.php
Line: 292
Function: require_once
Molnupiravir INN
Composition : Each Capsule Contains Molnupiravir INN 200mg.
Indication : It is indicated for the treatment of mild to
moderate coronavirus disease 2019 (COVID-19) in adults with a positive
SARS-COV-2 diagnostic test and who have at least one risk factor for developing
severe illness.
Dosage and administration: Adults:The recommended dose of Molnupiravir is 800 mg (four
200 mg capsules) taken orally every 12 hours for 5 days.The safety and efficacy
of Molnupiravir when administered for periods longer than 5 days have not been
established. Molnupiravir should be
administered as soon as possible after a diagnosis of COVID-19 has been made
and within 5 days of symptom onset.
Paediatric population: The safety and efficacy of Molnupiravir in patients
below 18 years of age have not been established. No data are available.
Or, as directed by the registered physician.
Use in pregnancy and lactation :
Pregnancy: There
are no data from the use of Molnupiravir in pregnant women. Studies in animals
have shown reproductive toxicity. Molnupiravir is not recommended during
pregnancy. Women of childbearing potential should use effective contraception
for the duration of treatment and for 4 days after the last dose of
Molnupiravir.
Breast-feeding: It is unknown whether Molnupiravir or
any of the components of molnupiravir are present in human milk, affect human
milk production, or have effect on the breastfed infant. Animal lactation
studies with molnupiravir have not been conducted.Based on the potential for
adverse reactions on the infant from Molnupiravir, breast-feeding is not
recommended during treatment and for 4 days after the last dose of
Molnupiravir.
Packing: Each box contains 40’s capsules in container.
Severity: Core Warning
Message: Module 'oci8' already loaded
Filename: Unknown
Line Number: 0
Backtrace:
Severity: Warning
Message: rewind() expects parameter 1 to be resource, boolean given
Filename: drivers/Session_files_driver.php
Line Number: 188
Backtrace:
Severity: Warning
Message: filesize(): stat failed for /var/cpanel/php/sessions/ea-php56/ci_sessionef018a09d78aac86faec626d87aecf4dd7ea6132
Filename: drivers/Session_files_driver.php
Line Number: 192
Backtrace:
